Frankfurt - Delayed Quote • EUR BioCryst Pharmaceuticals, Inc. (BO1.F) Follow Compare 8.39 -0.49 (-5.47%) As of 1:08:53 PM GMT+1. Market Open. Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for BO1.F 1D 5D 1.40% 1M 8.20% 3M 12.76% 6M 19.06% YTD 14.70% 1Y 52.95% 5Y 217.95% All -69.48% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: BO1.F View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations BioCryst Launches ORLADEYO® (berotralstat) in Portugal Exploring Three High Growth Tech Stocks In The United States BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress BioCryst to Report Fourth Quarter 2024 Financial Results on February 24 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock BioCryst price target raised to $12 from $10 at Evercore ISI Exploring High Growth Tech Stocks In January 2025 BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127%